Clinical Trial Update: Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating a BCMA/CD70-targeted CAR-T therapy for refractory pediatric rheumatic diseases is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Dermatomyositis
• Polyarticular Juvenile Idiopathic Arthritis
• Sjogren Syndrome
• Systemic Sclerosis

Drugs mentioned

• BCMA/CD70-targeted CAR-T therapy

Snippet

Sponsor: Chongqing Precision Biotech Co., Ltd | Conditions: Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis | Phase 1 | Status: RECRUITING